

Executive Summary of Collaborative Working Project between Astellas Pharma Ltd and The Christie NHS Foundation Trust:

Service Optimisation of the Bladder Cancer Pathway

Date June 2026

Objective:

To undertake a “service review of the Bladder Cancer Pathway” in partnership with Bionical Health Ltd and *The Christie NHS Foundation Trust* to support the re-design of that pathway to optimise the cancer centres Bladder Cancer Pathway.

Summary:

The efficient referral and testing pathways are an important part of successful Bladder Cancer patient management.

The Bladder Cancer Pathway Service Optimisation Programme will enable cancer centres to work in partnership with Astellas/Bionical Health to review this part of the pathway to identify any inefficiencies, wastage, delays in testing turnaround times & bottlenecks etc. that may be causing an ineffective service.

Astellas are committed to supporting the NHS with the Bladder Cancer Pathway. By working in partnership, Astellas are at the forefront of driving innovation and change for the positive benefit of patients and assisting the NHS in delivering high standards of care. Working in partnership between Astellas, Bionical Health and cancer centres, pooling of joint expertise to review this part of the pathway, will support health professionals in their desire to improve patient well-being.

The desired outcome of the project will be to optimise the pathway to improve the pathway for patients to be identified and access appropriate treatment options. The timelines for the project will be June 2026 – December 2026 and the total value of this project is £8550 fully funded by Astellas

Benefits of Project

Patients	<ul style="list-style-type: none">• May lead to a more beneficial patient experience of the service.• Potential for reduced waiting times.• Earlier access to treatment and management of any treatment related toxicities• Potential for reduction in inpatient hospital stays
NHS	<ul style="list-style-type: none">• Service optimisation may lead to improved service delivery and improved capacity within Bladder Cancer pathway.• Improvement in baseline metrics such as waiting times and other such national targets.• An efficient service may lead to a more sustainable service.• May lead to improved patient satisfaction of the service they receive.• May lead to staff satisfaction and retention.

Astellas Pharma Ltd	<ul style="list-style-type: none">• recognition of Astellas offering value added services that benefit NHS Bladder cancer services.• development of relationships with cancer centres through working in partnership to solve unmet needs.• service improvement may lead to more throughput of patients which may lead to a benefit of increased use of Astellas products.• enhancing skill base of service re-design expertise in-house.
------------------------	--